Eight-year incidence and progression of DR in the MESA
| Incident DR | DR progression | DR improvement | Incident VTDR | Incident PDR | Incident CSME | |||||||
| No at risk | Incidence (%) | No at risk | Incidence (%) | No at risk | Incidence (%) | No at risk | Incidence (%) | No at risk (%) | Incidence (%) | No at risk | Incidence (%) | |
| Total | 365 | 70 (19.2) | 133 | 23 (17.3) | 133 | 31 (23.3) | 482 | 13 (2.7) | 491 | 9 (1.8) | 465 | 10 (2.2) |
| White | 93 | 18 (19.4) | 21 | 2 (9.5) | 21 | 3 (14.3) | 112 | 1 (0.9) | 113 | 1 (0.9) | 106 | 1 (0.9) |
| African American | 115 | 16 (13.9) | 54 | 12 (22.2) | 54 | 15 (27.8) | 164 | 3 (1.8) | 167 | 3 (1.8) | 154 | 2 (1.3) |
| Hispanic | 111 | 25 (22.5) | 47 | 7 (14.9) | 47 | 10 (21.3) | 151 | 8 (5.3) | 156 | 4 (2.6) | 149 | 6 (4.0) |
| Chinese | 46 | 11 (23.9) | 11 | 2 (18.2) | 11 | 3 (27.3) | 55 | 1 (1.8) | 55 | 1 (1.8) | 56 | 1 (1.8) |
| P value | 0.318 | 0.573 | 0.623 | 0.116 | 0.794 | 0.285 | ||||||
DR progression/improvement was defined as a two-step or more change (+/−) in the DR severity scale as described in online supplemental table 1.
CSME, clinically significant macular oedema; DR, diabetic retinopathy; MESA, Multi-Ethnic Study of Atherosclerosis; PDR, proliferative diabetic retinopathy; VTDR, vision-threatening diabetic retinopathy.